Click below for full prescribing information:
The European Commission (EC) granted the marketing authorization for SPEDRA™ (avanafil) for the treatment of erectile dysfunction (ED) in the European Union (EU). The approval of the marketing authorization application (MAA) by the EC follows the positive recommendation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) in April 2013. SPEDRA, a PDE5 inhibitor, is the first new chemical entity (NCE) approved for ED in over a decade.
A medical information healthcare professional is available to answer questions from healthcare professionals during business hours, Monday – Friday from 09:00 – 17:00 Local Time, at:
- +31 208084787 (Amsterdam)
- +44 2030516658 (United Kingdom)
If you are a patient, please discuss any questions you may have with your healthcare provider.
After hours: You may leave a message after hours from 17:00 – 9:00 Local Time, Monday – Friday and all day Sunday, Saturday, and holiday.
For information about VIVUS' Products approved in the US, click here